HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion: Difference between revisions
| [pending revision] | [pending revision] |
| Line 65: | Line 65: | ||
|A small case series suggested an intermediate prognosis, with a poor response to treatment and high levels of measurable residual disease at the end of induction<ref>{{Cite journal|last=Fournier|first=Benjamin|last2=Balducci|first2=Estelle|last3=Duployez|first3=Nicolas|last4=Clappier|first4=Emmanuelle|last5=Cuccuini|first5=Wendy|last6=Arfeuille|first6=Chloé|last7=Caye-Eude|first7=Aurélie|last8=Delabesse|first8=Eric|last9=Bottollier-Lemallaz Colomb|first9=Elodie|date=2019|title=B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL|url=https://pubmed.ncbi.nlm.nih.gov/31921638|journal=Frontiers in Oncology|volume=9|pages=1374|doi=10.3389/fonc.2019.01374|issn=2234-943X|pmc=6914849|pmid=31921638}}</ref>. | |A small case series suggested an intermediate prognosis, with a poor response to treatment and high levels of measurable residual disease at the end of induction<ref>{{Cite journal|last=Fournier|first=Benjamin|last2=Balducci|first2=Estelle|last3=Duployez|first3=Nicolas|last4=Clappier|first4=Emmanuelle|last5=Cuccuini|first5=Wendy|last6=Arfeuille|first6=Chloé|last7=Caye-Eude|first7=Aurélie|last8=Delabesse|first8=Eric|last9=Bottollier-Lemallaz Colomb|first9=Elodie|date=2019|title=B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL|url=https://pubmed.ncbi.nlm.nih.gov/31921638|journal=Frontiers in Oncology|volume=9|pages=1374|doi=10.3389/fonc.2019.01374|issn=2234-943X|pmc=6914849|pmid=31921638}}</ref>. | ||
|} | |} | ||
==Individual Region Genomic Gain/Loss/LOH== | ==Individual Region Genomic Gain/Loss/LOH== | ||